Business Wire

Celltrion Healthcare Showcases Positive Data on Switching and Monotherapy With Remsima ® SC in Patients With Inflammatory Bowel Disease at UEG Week Virtual 2021

Share

Celltrion Healthcare today announced two data sets relating to the use of the subcutaneous formulation of infliximab, Remsima® SC (CT-P13 SC), in inflammatory bowel disease (IBD) at a poster presentation at United European Gastroenterology (UEG) Week 2021, held virtually from October 3- 5.

The first study investigated clinical impact of switching from intravenous (IV) to subcutaneous (SC) treatment of infliximab in patients with Crohn’s disease (CD) or ulcerative colitis (UC) from the pivotal randomised controlled trial of CT-P13 SC.3 65 patients (25 CD patients, 40 UC patients) were included in the CT-P13 IV arm in which patients received CT-P13 5 mg/kg IV every 8 weeks from week 6 until week 22. At week 30, patients switched to receive CT-P13 SC every 2 weeks up to week 54 (dose 120 mg or 240 mg for patients < 80 kg or ≥ 80 kg, respectively).1

Results showed switching from IV to SC infliximab conferred more favourable clinical outcomes in terms of pharmacokinetics, efficacy, and possibly, immunogenicity. There was a significant difference in Ctrough pre- and post-switch (median Ctrough Levels at 2.05 μg/mL (interquartile range [IQR], 0.10-3.61) and 21.10 μg/mL (IQR, 11.30-26.50) pre- and post-switch, respectively; p<0.0001). The proportion of patients with Ctrough exceeding target exposure (5 μg/mL) was significantly higher post-switch (36/41, 87.80%) than pre-switch (8/41, 19.51%; p<0.00001). In terms of efficacy, clinical response rates were comparable at both pre- and post-switch timepoints (40/49 [81.63%] vs 44/49 [89.80%], respectively; p=0.3873). However, faecal calprotectin (FC) levels were significantly lower post-switch compared with pre-switch. Anti-drug antibody (ADA) and neutralising antibody (NAb) positivity were also numerically lower post-switch although statistical significance was not reached.1

The second study presented investigated comparable efficacy of subcutaneous (SC) infliximab monotherapy versus combination therapy with immunomodulators using data from the pivotal randomised controlled trial of CT-P13 SC in active CD or UC.3

Patients with active CD or UC who were tumour necrosis factor (TNF) inhibitor treatment–naïve were enrolled and received induction therapy with CT-P13 5 mg/kg intravenously (IV) at week 0 and week 2, after which they were randomised to continue therapy with CT-P13 IV or receive CT-P13 SC 120 mg (patients<80 kg) or 240 mg (patients ≥80 kg) every 2 weeks from week 6 to week 54. Of 66 patients, 37 and 29 received monotherapy and combination therapy, respectively. The results show there was no significant difference between groups in the number of patients with Ctrough level exceeding target exposure with both groups exceeding target exposure throughout the study period (target exposure: 5 μg/mL; monotherapy: 28/29, 96.55%; combination therapy: 23/24, 95.83%; p>0.9999). Clinical response rates in terms of CDAI-100 and partial Mayo response were comparable between arms and there was no difference in immunogenicity between the groups despite the concomitant use of immunomodulators in the combination therapy group.2

Professor Walter Reinisch, Director of Clinical IBD Study Group, Department of Gastroenterology and Hepatology, Medical University of Vienna and the presenting author of the poster presentation said, “The post-hoc analysis indicates that switching from IV to SC infliximab will deliver comparable clinical outcomes for patients with inflammatory bowel disease, including those with Crohn's disease and ulcerative colitis, further highlighting the potential of SC infliximab as an alternative administration route. Infliximab SC offers patients and caregivers the possibility of more convenient care with the potential for in-home use.”

Professor Shomron Ben-Horin, MD, Department of Gastroenterology, Chaim Sheba Medical Center in Israel, and the presenting author of the poster presentation said, “These exploratory results suggest that SC infliximab monotherapy may provide comparable clinical outcomes and immunogenicity to combination therapy with immunomodulators, thereby advancing the concept of SC infliximab monotherapy as a viable treatment option for IBD patients.”

- ENDS -

Notes to Editors:

About inflammatory bowel disease

Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disabling gastrointestinal disorders that impact every aspect of a patient’s life.4 They affect an estimated 5 million people globally.5 IBDs account for substantial costs to the healthcare system and society - the direct healthcare costs of IBDs are estimated to be €4.6-5.6 billion per year.6

About CT-P13 (biosimilar infliximab)

CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including Rheumatoid Arthritis (RA) and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 97 countries (as of September 2021) including the US, Canada, Japan and throughout Europe.

About Remsima® (CT-P13) intravenous (IV) formulation7

Remsima® IV is usually given as 3 mg per kg/body weight in rheumatoid arthritis (RA) and as 5 mg per kg/body weight for the other indications. Infliximab IV is given as an infusion over two hours. All patients are monitored for any reactions during the infusion and for at least one to two hours afterwards.

About Remsima® CT-P13 subcutaneous (SC) formulation

A 120 mg fixed dose of Remsima® SC has been granted marketing authorisation in the EU, in adults regardless of body weight, in all previously approved indications in adult for the IV formulation. Remsima® SC has three available devices; via a pre-filled pen (auto injector), pre-filled syringe or pre-filled syringe with needle safeguard.7 The SC formulation has the potential to enhance treatment options for the use of infliximab by providing high consistency in drug exposure and a convenient method of administration.

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com

References

1 Stefan Schreiber, et al. Switching from intravenous to subcutaneous infliximab in patients with active inflammatory bowel disease: Post-hoc analysis of pre-/post- switch outcomes from a multicentre, randomised controlled pivotal trial. Poster (P0472). Presented at UEG Week Virtual 2021.

2 Geert D’Haens, et al. Comparison of combination subcutaneous infliximab and an immunomodulator versus subcutaneous infliximab monotherapy: Post-hoc analysis of a randomised clinical trial. Poster (P0467). Presented at UEG Week Virtual 2021.

3 Schreiber S, et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology. 2021; 160:2340-2353

4 Molodecky, N. A, et al. (2012). Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142(1), 46-54. Retrieved from: www.gastrojournal.org/article/S0016-5085(11)01378-3/pdf [Last accessed September 2021].

5 The European Federation of Crohn’s & Ulcerative Colitis Associations. What is IBD? Science. Retrieved from www.efcca.org/en/science [Last accessed September 2021].

6 Burisch. J, et al. (2013). The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis, 7(4), 322-337.Retrieved from: https://www.sciencedirect.com/science/article/pii/S1873994613000305?via%3Dihub [Last accessed September 2021].

7 European Medicines Agency Summary of Product Characteristics (SmPC). Infliximab. Available at https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf [Last accessed September 2021].

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:

Holly Barber
hbarber@hanovercomms.com
+44 (0) 7759 301620

Donna Curran
dcurran@hanovercomms.com
+44 (0) 7984 550312

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation

Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release

Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private

Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding

Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår

V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release

V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust

Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release

Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo

HiddenA line styled icon from Orion Icon Library.Eye